The Future of Medicine Is Powered by AI and Synthetic Antibodies
Antibodies are proteins that can bind to specific molecules and neutralize them, such as viruses or bacteria.
LabGenius, a London-based biotech company, is using machine learning to design new antibodies that are more potent and diverse than those found in nature.
The company’s AI platform, called EVA, can generate billions of synthetic antibody sequences and test them in the lab for their binding affinity and stability.
EVA can also learn from the experimental data and optimize the antibody design process, creating novel sequences that humans would not think of.
LabGenius has partnered with several pharmaceutical companies to develop new antibody therapies for various diseases, such as cancer, inflammation, and infectious diseases.
The company is developing novel antibody-based immunotherapies, such as T-cell engagers (TCEs), that can selectively kill tumor cells and recruit immune cells to fight cancer.
The company hopes to accelerate the discovery and development of new drugs by using AI to explore the vast space of possible antibodies.
LabGenius is one of the pioneers of applying AI to protein engineering, a field that has huge potential for medicine.
The company believes that AI can help unlock the secrets of biology and create better treatments for patients.